



(86) Date de dépôt PCT/PCT Filing Date: 2002/11/30
(87) Date publication PCT/PCT Publication Date: 2003/07/03
(45) Date de délivrance/Issue Date: 2015/03/17
(85) Entrée phase nationale/National Entry: 2004/06/10
(86) N° demande PCT/PCT Application No.: EP 2002/013545
(87) N° publication PCT/PCT Publication No.: 2003/054541
(30) Priorité/Priority: 2001/12/12 (EP01129564.9)

(51) Cl.Int./Int.Cl. *A61K 39/395* (2006.01),
A61K 31/7088 (2006.01), *A61P 9/00* (2006.01),
C12Q 1/68 (2006.01), *G01N 33/68* (2006.01),
C07K 16/18 (2006.01), *C12N 15/11* (2006.01)

(72) Inventeurs/Inventors:
KLUXEN, FRANZ-WERNER, DE;
HENTSCH, BERND, DE;
EHRING, THOMAS, DE;
BRAENDLE, MARIAN, DE;
HOHEISEL, JOERG DIETRICH, DE;
FROHME, MARCUS, DE;
ZUBAKOV, DIMITRI, DE

(73) Propriétaire/Owner:

(54) Titre : INHIBITION DE LA TRISTETRAPROLINE VISANT A PROTEGER LE COEUR CONTRE LES LESIONS
CARDIAQUES

(54) Title: INHIBITION OF TRISTETRAPROLINE FOR PROTECTION OF THE HEART FROM CARDIAC INJURIES

(57) **Abrégé/Abstract:**

The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering from such conditions and to methods of screening compounds for their ability to enhance TNF α biosynthesis.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 03/054541 A3

- (51) International Patent Classification⁷: **G01N 33/68**, C12Q 1/68 (74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (21) International Application Number: PCT/EP02/13545 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 30 November 2002 (30.11.2002) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 01129564.9 12 December 2001 (12.12.2001) EP
- (71) Applicant (*for all designated States except US*): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): **KLUXEN, Franz-Werner** [DE/DE]; Bahnhofstr. 39, 64367 Mühlthal (DE). **HENTSCH, Bernd** [DE/DE]; Gervinusstrasse 8, 60322 Frankfurt (DE). **EHRING, Thomas** [DE/DE]; Königstrasse 129, 42853 Remscheid (DE). **BRÄNDLE, Marian** [DE/DE]; Sonnenweg 5, 72181 Starzach (DE). **HOHEISEL, Jörg, Dietrich** [DE/DE]; Lempenseite 18-5, 69168 Wiesloch (DE). **FROHME, Marcus** [DE/DE]; Danzigerstrasse 6, 68535 Edingen (DE). **ZUBAKOV, Dimitri** [RU/DE]; Oberer Rainweg 8, 69117 Heidelberg (DE).
- Published:**
— with international search report
- (88) Date of publication of the international search report: 6 November 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: INHIBITION OF TRISTETRAPROLINE FOR PROTECTION OF THE HEART FROM CARDIAC INJURIES

(57) Abstract: The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering from such conditions and to methods of screening compounds for their ability to enhance TNF α biosynthesis.



WO 03/054541 A3

Inhibition of Tristetraproline for protection of the heart from cardiac injuries

5

Field of the invention

The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing
10 TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering from such conditions and to methods of screening compounds for their ability to enhance TNF α biosynthesis.

Background of the invention

15 TNF α is a potent cytokine that is released from many cell types. TNF α also exists in a cell-membrane bound, higher molecular weight form on cells, and this form also appears to mediate a variety of biological effects. TNF α is thought to have few roles in normal development and physiology; however, it exerts harmful and destructive effects on many tissues in many disease states (Tracey et al., Ann.
20 Rev. Med 1994; 45:491). Disease states in which TNF α has been shown to exert a major role include septic shock syndrome, cancer cachexia, rheumatoid arthritis, etc.

In contrast, experimental studies from several laboratories have shown that the
25 adult mammalian heart synthesizes TNF α mRNA after certain forms of stress (Bader et al., Proc. Natl. Acad. Sci. USA. 1994; 91:11831; Giroir et al., J. Clin. Invest. 1992; 90:693; Giroir et al., Am. J. Physiol. 1994; 267:H118.)

The repeated observation that TNF α is expressed in virtually all forms of cardiac
30 injury in both large and small mammals, including but not limited to myocardial infarction (Mauri et al., J. Intern. Med. 1989; 225:333; Basaran et al., Angiology. 1993; 44:332), unstable angina (Matsumori et al., Br. Heart J. 1994; 72:566), hemodynamic overloading (Kapadia et al., J. Clin. Invest. 1995; 96:1042),

- 2 -

myocardial reperfusion injury (Lefer et al., Science. 1990; 249:61; Herskowitz et al., Am. J. Pathol. 1995;146:419), hypertrophic cardiomyopathy (Matsumori et al., Br. Heart. J. 1994;72:561), and end-stage congestive heart failure (Levine et al., N. Engl. J. Med. 1990; 223:236; Torre-Amione et al., Circulation. 1996; 93:704)
5 suggests that $\text{TNF}\alpha$ may act as a phylogenetically conserved "innate stress response gene" in the heart.

In this regard, the observation that $\text{TNF}\alpha$ confers resistance to hypoxic stress in the adult cardiac tissue suggests that $\text{TNF}\alpha$ production by the injured and/or
10 stressed cardiac tissue may serve as a local autocrine/paracrine/ juxtacrine mechanism for protecting neighboring cells within the heart (Nakano et al., Circulation. 1998; 97:1392)

It is well known that short periods of coronary artery occlusion followed by
15 reperfusion confers protection of the heart from later periods of otherwise lethal ischemic conditions. However, this first protective period ends after several hours. 24h after the initial ischemia, a 'second window of protection' (SWOP) occurs, which may last for several days, depending on the species used and the experimental conditions. Besides occlusion/reperfusion periods, a number of
20 substances like adenosine and lipopolysaccharide (LPS) are also known to induce a SWOP.

Among others, the expression of iNOS (inducible NO-synthase) is considered to be an important mediator of the SWOP. iNOS as itself is induced by $\text{TNF}\alpha$, which
25 is expressed e.g. after induction of a SWOP by LPS. The expression of $\text{TNF}\alpha$ seems to be necessary for the development of the SWOP. Therefore an elevated level of $\text{TNF}\alpha$ may thus be of therapeutic use in conditions which may be improved, at least in part, by increasing $\text{TNF}\alpha$ production including but not limited to cardiac diseases and/or cardiac injuries and/or for the prevention of
30 reperfusion damage.

Hence it follows that there is a need for medicaments enhancing the level of $\text{TNF}\alpha$ in individuals suffering from the a.m. mentioned conditions, for methods for

- 3 -

screening compounds for their ability to enhance the $\text{TNF}\alpha$ level and for methods of identifying and diagnosing individuals at increased risk for or suffering from such conditions.

- 5 The present invention relates to a novel approach to the treatment of conditions which may be improved, at least in part, by increasing $\text{TNF}\alpha$ production. This approach involves the protein tristetraprolin (TTP), cDNA and cRNA of TTP and anti-TTP antibodies and their fragments.
- 10 TTP (Lai et al, J. Biol. Chem. 1990; 265:16556), also known as Nup475 (DuBois et al, J. Biol. Chem. 1990; 265:19185) and TIS11 (Varnum et al, Oncogene 1989; 4:119; Varnum et al, Mol. Cell. Biol. 1991; 11:1754), is a widely distributed 33 kDa phosphoprotein encoded by the immediate-early response gene, Zfp-36 (Taylor et al, Nucl. Acids Res. 1991; 19:3454). This gene has been mapped to
- 15 chromosome 7 in the mouse, and the equivalent human gene, ZFP36, has been mapped to chromosome 19q 13.1 (Taylor et al, Nucl. Acids Res. 1991; 19:3454). TTP is the prototype of a group of proteins containing two or more highly conserved putative zinc fingers of the CCCH class (Varnum et al, Mol. Cell. Biol. 1991; 11:1754; Taylor et al, Nucleic Acids Res. 1991; 19:3454; Gomperts et al,
- 20 Oncogene. 1990; 5:1081; Ma et al, Oncogene. 1994; 9:3329). In addition, the protein has been shown to bind Zn^{2+} and has been localized to the cell nucleus in mouse fibroblasts (DuBois et al, J. Biol. Chem. 1990; 265:19185), suggesting that it may be a transcription factor. Serum or other mitogen stimulation of quiescent fibroblasts causes rapid serine phosphorylation and nuclear to cytosolic
- 25 translocation of TTP (Taylor et al., J. Biol. Chem. 1995; 270:13341), both of which are likely to modulate its function in cells.

Recently it was shown that TTP plays a role in $\text{TNF}\alpha$ regulation in macrophages (Carballo et al., Science 1998; 281:2001). TTP expression is induced by

30 lipopolysaccharides and $\text{TNF}\alpha$. TTP is able to bind to an AU-rich element (ARE) in the 3 prime end of the $\text{TNF}\alpha$ mRNA molecule, thus destabilizing the $\text{TNF}\alpha$ mRNA.

26474-862

- 4 -

In WO 97/42820 the properties of TTP have been used for the treatment of diseases which are associated with $\text{TNF}\alpha$ excess like septic shock syndrome, cancer cachexia, rheumatoid arthritis etc. Methods of treatment of such diseases by increasing the TTP level are described as well as methods for selecting
5 compounds for their ability to inhibit $\text{TNF}\alpha$ production and methods for identifying an individual at increased risk to the effects of $\text{TNF}\alpha$ excess.

WO 01/12213 provides methods of regulating the destruction of mRNA molecules containing an AU-rich element (ARE), for example, methods of stimulating the
10 degradation of an mRNA molecule encoding $\text{TNF}\alpha$ and methods of inhibiting the degradation of an mRNA molecule encoding granulocyte-macrophage stimulating factor for the treatment of granulocytopenia.

The function of TTP in an individual at risk for or suffering from a condition which
15 may be improved, at least in part, by increasing $\text{TNF}\alpha$ production including but not limited to cardiac diseases and/or cardiac injuries was heretofore unknown.

Summary of the invention

It is an object of the present invention to provide screening assays for selecting
20 compounds for their ability to increase $\text{TNF}\alpha$ production.

It is another object of the invention to provide assays for the identification of an individual at increased risk for or suffering from conditions which may be improved, at least in part, by increasing $\text{TNF}\alpha$ production including but not limited
25 to cardiac diseases and/or cardiac injuries and/or for the identification of individuals needing a therapy for the prevention of reperfusion damage.

26474-862

- 4a -

According to one embodiment, the invention relates to a method for screening a compound for its ability to enhance TNF α production by inhibiting and/or reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

- a) contacting the compound with a cell-free sample comprising an expression
5 construct able to express a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE fragments known to destabilize the TNF α mRNA fused to a reporter gene in the presence of TTP under conditions such that the reporter protein can be expressed; and b) determining the level of expression of the reporter protein and comparing that level to a level of expression obtained in the absence of
10 the compound; and c) selecting compounds which enhance the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.

According to another embodiment, the invention relates to a method for screening a compound for its ability to enhance TNF α production by inhibiting and/or
15 reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

- a) contacting said compound with a cell-free sample comprising TNF α mRNA, in the presence of TTP under conditions such that TNF α can be expressed; b) determining the level of expression of TNF α and comparing the level of produced TNF α to a level of TNF α obtained in the absence of said compound; and c) selecting compounds
20 which enhance the expression of TNF α in comparison to that level of expression obtained in the absence of the compound.

According to another embodiment, the invention relates to a method for screening a compound for its ability to enhance TNF α production by inhibiting and/or reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

- 25 a) contacting the compound with a cell line expressing TTP and TNF α or, instead of TNF α , a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE fragments known to destabilize the TNF α mRNA fused to a reporter gene; b) determining the level of expression of TNF α or of the reporter protein and comparing that level to a level of expression obtained in the absence of the

26474-862

- 4b -

compound; and c) selecting compounds which enhance the expression of TNF α or the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.

According to another embodiment, the invention relates to the use of
5 the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, to induce or enhance TNF α production in an individual by one or both of inhibiting and reversing the binding of TTP to TNF α mRNA, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA.

10 According to another embodiment, the invention relates to the use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, for the treatment of one or both of cardiac diseases and cardiac injuries, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA,
15 and wherein one or both of the cardiac disease and cardiac injury is a hemodynamic overloading, myocardial reperfusion injury, hypertrophic cardiomyopathy, end-stage congestive heart failure, ischemic condition, myocardial infarction or unstable angina.

According to another embodiment, the invention relates to the use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of
20 anti-TTP antibodies, for the prevention of reperfusion damage, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA.

In another embodiment of the invention TTP cDNA derived sequences may be used for the design of primers that can be applied for any PCR based method
25 for the quantitation of TTP mRNA. The quantitation of TTP mRNA levels in biological samples may be used as a diagnostic tool to detect altered gene expression.

26474-862

- 4c -

In one embodiment of the invention TTP cDNA derived sequences may be used for the design of primers that can be applied for any PCR based method for the quantitation of TTP mRNA. The quantitation of TTP mRNA levels in biological samples may be used as a diagnostic tool to detect altered gene
5 expression.

- 5 -

A further object of the present invention is to provide active compounds having the ability to increase $\text{TNF}\alpha$ production by inhibiting and/or reversing the binding of TTP to $\text{TNF}\alpha$ mRNA like anti-TTP antibodies or fragments thereof, cDNA or cRNA of TTP mRNA or fragments thereof able to hybridize with TTP mRNA or
5 other compounds selected by an assay as described above and below and medicaments comprising these compounds.

In yet another embodiment, the present invention relates to the use of said active compounds able to inhibit and/or reverse the binding of TTP to $\text{TNF}\alpha$ mRNA for
10 inducing or increasing the $\text{TNF}\alpha$ production in a individual.

It is also an embodiment of the present invention to provide the use of the active compounds for the manufacture of a medicament for the treatment of an individual at risk for or suffering from conditions which may be improved, at least
15 in part, by increasing $\text{TNF}\alpha$ production including but not limited to cardiac diseases and/or cardiac injuries and/or for the prevention of reperfusion damage.

Further objects and advantages of the invention will be clear from the description that follows.

20

Brief description of the figures

Figure 1. Detection of TTP mRNA in dog hearts by RT-PCR.

1. 8h reperfusion control (sham-surgery)
2. 4h reperfusion control (sham-surgery)
- 25 3. 16h reperfusion (surgery)
4. 8h reperfusion (surgery)
5. 4h reperfusion (surgery)

RNAs from the indicated sources were used for RT-PCR analysis.
30 RNAs were reverse transcribed using standard methods and subsequently subjected to PCR using short oligodesoxynukleotides as primers designed from the original dog TTP sequence .

Detailed description of the invention

The objects of the present invention are achieved on the basis of the unexpected finding that the expression of the protein tristetraproline (TTP) is upregulated in a time dependent manner in cardiac tissue after occlusion of a coronary artery and following reperfusion (Fig. 1).

As indicated above, $\text{TNF}\alpha$ production by the injured and/or stressed cardiac tissue may serve as a local autocrine/paracrine/ juxtacrine mechanism for protecting neighboring cells. Accordingly, the ability of TTP to regulate $\text{TNF}\alpha$ production in heart is of considerable pharmaceutical importance.

The finding that TTP is expressed in heart after occlusion of a coronary artery followed by reperfusion and the availability of the amino acid sequence of human TTP (Taylor et al, Nucl. Acids Res. 1991, 19:3454) and its encoding sequence (eg GenBank accession number M63625) permits the development of assays for screening compounds which can be used for the prevention and/or treatment of conditions which may be improved, at least in part, by increasing $\text{TNF}\alpha$ production including but not limited to cardiac diseases, cardiac injuries and/or for the prevention of reperfusion damage and of methods for identifying and diagnosing individuals at increased risk for or suffering from such conditions.

The term "cardiac diseases and/or cardiac injuries" refers to diseases and/or injuries like or hemodynamic overloading, myocardial reperfusion injury, hypertrophic cardiomyopathy, end-stage congestive heart failure and/or a ischemic condition or a consequence thereof like myocardial infarction or unstable angina.

In one example of a screening assay according to the invention, the full length human TTP cDNA is inserted in a suitable eukaryotic expression vector (under control of a strong promoter like SV40, CMV, or an inducible promoter (e.g. tet on-off system)) carrying a selection marker like neomycin, zeozin, hygromycin, or other substances for selection of recombinant cells. This expression vector is transfected by standard methods into a cell line like H9C2, COS-1, COS-7,

- 7 -

HEK293, HEK293 EBNA, CHO, BHK HeLA or similar cell lines for the expression of cDNAs and selected for a stable cell line by adding the antibiotic. In this way, either a monoclonal or a polyclonal cell line is selected.

- 5 A second plasmid is constructed using a promoter like SV40, CMV or similar fused to TNF α gene or a reporter gene like luciferase, CAT, β -galactosidase and a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE (AU rich element) fragments known to destabilize the TNF α mRNA (bases 1197 to 1350 of GenBank accession number X02611). The vector in addition
10 carries a selection marker that is different from the first vector. Transfection can be effected using art-recognized techniques.

After transfection and selection of the second plasmid the cell line can be used for detecting substances that interfere with the activity of TTP.

15

Alternatively, the plasmid carrying TTP and the plasmid carrying the TNF α gene or reporter gene can be mixed and subsequently transfected using standard techniques in a cell line as described above.

- 20 Such a cell line can be used for an assay for the screening of a compound for its ability to enhance TNF α production by inhibiting and/or reverse the binding of TTP to TNF α mRNA comprising for instance the steps:

- a) contacting the compound with the cell line expressing TTP and TNF α or,
25 instead of TNF α , a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE fragments known to destabilize the TNF α mRNA fused to a reporter gene, and
b) determining the level of expression of TNF α or of the reporter protein and comparing that level to a level of expression obtained in the absence of the
30 compound, and

- 8 -

- c) selecting compounds which enhance the expression of $\text{TNF}\alpha$ or the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.

5 The test compounds are added and after 24 to 72 h the activity of the reporter gene is measured using an enzyme activity reader or a fluorescence signal detector, or in the case wherein the cell line expresses $\text{TNF}\alpha$, with antibodies directed against $\text{TNF}\alpha$ or other art-recognized techniques; the observed values are used for the determination of the activity of TTP.

10

Substances that increase TTP activity can be detected by a higher activity of the reporter gene than in comparison to the non-treated control cells.

A substance that inhibits and/or reverses the binding of TTP to the ARE located
15 in the 3' end of the $\text{TNF}\alpha$ or reporter mRNA will stabilize the mRNA and lead to a higher production of $\text{TNF}\alpha$ or reporter protein than in the absence of such a compound.

In another example of a screening assay according to the invention the assay
20 comprises the following steps:

- a) contacting the compound to be screened with a cell-free sample comprising an expression construct able to express a part of the 3' untranslated region of the $\text{TNF}\alpha$ mRNA which encompasses the ARE
25 fragments known to destabilize the $\text{TNF}\alpha$ mRNA fused to a reporter gene in the presence of TTP under conditions such that the reporter protein can be expressed, and
- b) determining the level of expression of the reporter protein and comparing that level to a level of expression obtained in the absence of the
30 compound, and
- c) selecting compounds which enhance the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.

A further example of a screening assay according to the invention the assay comprises the following steps:

- 5 a) contacting said compound with a cell-free sample comprising TNF α mRNA, in the presence of TTP under conditions such that expression of TNF α can be expressed, and
 - b) determining the level of expression of TNF α and comparing the level of produced TNF α to a level of TNF α obtained in the absence of said
10 compound and
 - c) selecting compounds which enhance the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.
- 15 Compounds which inhibit and/or reverse the inhibitory activity of TTP can then be further assayed, using standard protocols, for stability, toxicity etc.

In one approach for identifying and/or diagnosing individuals at increased risk for or suffering from conditions which may be improved, at least in part, by increasing
20 TNF α production including but not limited to cardiac diseases and/or cardiac injuries or for identifying individuals needing a therapy for the prevention of reperfusion damage, a biological sample obtainable from said individuals may be examined for the presence of elevated amounts of TTP or TTP-mRNA.

- 25 For example, the detection of TTP can be effected by contacting the sample with an anti-TTP antibody and measuring the amount of TTP.

These assays can be accomplished by any of a number of methods. Such methods include immunoassays which include but are not limited to competitive
30 and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement

- 10 -

fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.

For example such an assay can be carried out by a method comprising the following steps:

- a) contacting a biological sample obtainable from said individual with anti-TTP antibodies under conditions that binding of the antibody to TTP can occur
- b) measuring the amount of TTP by ELISA or a method as mentioned above.

- 10 The anti-TTP antibody can be detected by a second antibody which further comprises a detectable label. The detectable label may be a radioisotope that is detected by autoradiography. Isotopes that are particularly useful for the purpose of the present invention are ^3H , ^{125}I , ^{131}I , ^{35}S and ^{14}C . The second antibodies may also be labeled with a fluorescent compound. The presence of a fluorescently-
15 labeled antibody is determined by exposing the immunoconjugate to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent labeling compounds include fluorescein, isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
- 20 Alternatively, the second antibody can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged immunoconjugate is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an
25 imidazole, an acridinium salt and an oxalate ester.

Similarly, a bioluminescent compound can be used to label the second antibody. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent

- 30 reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Bioluminescent compounds that are useful for labeling include luciferin, luciferase and acquorin.

- 11 -

Alternatively, the second antibody can be detectably labeled by linking the second antibody to an enzyme. When the antibody-enzyme conjugate is incubated in the presence of the appropriate substrate, the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to detectably label polyspecific immunoconjugates include β -galactosidase, glucose oxidase, peroxidase and alkaline phosphatase.

Those of skill in the art will know of other suitable labels which can be employed in accordance with the present invention. The binding of marker moieties to antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy et al., Clin. Chim. Acta 1976, 70:1; Schurs et al., Clin. Chim. Acta 1977, 81:1; Shih et al., Intl J. Cancer 1990, 46: 1101; Stein et al., Cancer Res. 1990, 50:1330.

TTP or fragments thereof used for the production of antibodies can be synthesized recombinantly using common expression systems such as E. coli, baculovirus, Cos cells, Sf9 cells or eukaryotic cells as described in standard literature (e.g. Ausubel et al.(eds.): Current Protocols in Molecular Biology. John Wiley & Sons Inc., New York). The cDNA may also be modified by a tag like His(6), GST, FLAG or similar to aid the purification of the protein. The protein/polypeptide can then be purified by standard methods including chromatography (e.g., ion exchange, affinity, and size exclusion column chromatography), centrifugation, differential solubility, electrophoresis, or by any standard technique for purification of proteins.

Alternatively, TTP can be isolated from natural sources, using art recognized techniques as described above.

Polyclonal antibodies to recombinant TTP or to TTP isolated from natural sources used for the assay can be prepared using methods well-known to those of skill in the art. (See, for example, Green et al., "Production of Polyclonal Antisera," in Immunochemical Protocols, Manson, ed., pages 1-5, Humana Press 1992;

- 12 -

Williams et al., In DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al. (eds.), page 15, Oxford University Press 1995).

The immunogenicity of TTP can be increased through the use of an adjuvant,
5 such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of TTP or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like," such
10 portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

Although polyclonal antibodies are typically raised in animals such as horses,
15 cows, dogs, chicken, rats, mice, rabbits, guinea pigs, goats, or sheep, an anti-Zsig62 antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in WO 91/11465, and in Losman et al., Int. J. Cancer. 1990, 46: 310.

20

Alternatively, monoclonal anti-TTP antibodies can be generated. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., Nature 1975, 256: 495; Coligan et al. (eds.), Current Protocols in Immunology, Vol. 1, pages 2.5.1- 2.6.7
25 (John Wiley & Sons 1991), Picksley et al., "Production of monoclonal antibodies against proteins expressed in E coli," in DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al. (eds.), page 93 (Oxford University Press 1995)). Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising TTP, verifying the presence of antibody production by
30 removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the

- 13 -

antibodies from the hybridoma cultures. For example an anti-TTP antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic,
5 challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting
10 hybridomas.

Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., Nature Genet. 1994, 7: 13; Lonberg et al., Nature 1994, 368:856; Taylor et al., Int. Immun. 1994, 6: 579.

15

Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example Baines et al., "Purification of
20 Immunoglobulin G (IgG)," in Methods in Molecular Biology, Vol. 10, pages 79-104 (The Humana Press, Inc. 1992)).

In an alternative approach for identifying and diagnosing individuals at increased risk for or suffering from conditions which may be improved, at least in part, by
25 increasing $\text{TNF}\alpha$ production including but not limited to cardiac diseases and/or cardiac injuries or for identifying individuals needing a therapy for the prevention of reperfusion damage, a biological sample obtainable from said individual may be examined for the presence of elevated amounts of TTP-mRNA.

30 For example, the detection of TTP mRNA can be effected as follows:

- a) contacting a RNA-containing biological sample obtained from said individual with a detectable cDNA or cRNA of TTP or a fragment thereof able to bind

- 14 -

mRNA of TTP under conditions that hybridization with mRNA of TTP can occur

- b) measuring the amount of TTP-mRNA by any hybridization based method like northern blot, dot blot, RNase protection or similar methods relying on the hybridization of TTP cDNA or cRNA to the target RNA derived from the samples to be analyzed.

In a further approach of the invention TTP cDNA derived sequences may be used for the design of primers that can be applied for any PCR based method for the quantitation of TTP mRNA. The quantitation of TTP mRNA levels in biological samples may be used as a diagnostic tool to detect altered gene expression.

According to the present invention the term „cDNA" or „cRNA" refers to a single-stranded DNA or RNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of reverse transcription.

The above conditions are meant to serve as a guide and it is well within the abilities of one skilled in the art to adapt these conditions for use with a particular assay.

The finding that the expression of TTP is upregulated in cardiac tissue after occlusion of a coronary artery and following reperfusion provides a basis for therapy especially for the treatment of cardiac diseases and/or cardiac injuries and/or for a therapy for the prevention of reperfusion damage

For example, the individual may be treated with anti-TTP antibodies, preferably humanized antibodies or antibody fragments directed to TTP to inhibit the binding of TTP to $\text{TNF}\alpha$ mRNA and therefore to increase the production of $\text{TNF}\alpha$.

The term "antibody fragment" in the meaning of the present invention refers to a portion of an antibody such as F(ab')_2 , F(ab)_2 , Fab' , Fab , and the like. Regardless

- 15 -

of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term also includes a synthetic or a genetically engineered polypeptide that binds to a specific antigen, such as polypeptides consisting of the light chain variable region, "Fv" fragments consisting of the
5 variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

- 10 The term "humanized antibodies" refers to recombinant proteins in which murine complementarity determining regions of a monoclonal antibody have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.
- 15 Such antibodies can be produced as described above. For particular uses, it may be desirable to prepare fragments of anti-TTP antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be
20 produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $F(ab')_2$. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an
25 enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, in U.S. patent No. 4,331,647, Nisonoff et al., Arch Biochem. Biophys. 1960, 89:230; Porter, Biochem. J. 1959, 73:119; Edelman et al., in Methods in Enzymology Vol. 1, page 422 (Academic Press 1967). Other methods of cleaving antibodies, such
30 as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

- 16 -

For example, Fv fragments comprise an association of V_H and V_L chains. This association can be noncovalent, as described by Inbar et al. , Proc. Natl Acad. Sci. USA 1972, 69: 2659. Alternatively, the variable chains can be linked by an
5 intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde (see, for example, Sandhu, Crit. Rev. Biotech. 1992, 12: 437).

The Fv fragments may comprise V_H and V_L chains which are connected by a peptide linker. These single-chain antigen binding proteins (scFv) are prepared
10 by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector which is subsequently introduced into a host cell, such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing
15 scFvs are described, for example, Bird et al., Science 1988, 242: 423; U.S.- Patent No. 4,946,778; Pack et al., Biol.Technology 1993, 11: 1271.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can
20 be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody- producing cells (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2:106 (1991), Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in
25 Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), page 166, Cambridge University Press 1995, and Ward et al., "Genetic Manipulation and Expression of Antibodies," in Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), page 137, Wiley-Liss, Inc. 1995).

30 Alternatively, an anti-TTP antibody may be derived from a humanized monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain. Typical residues of human

- 17 -

antibodies are then substituted in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning
5 murine immunoglobulin variable domains are described, for example, by Orlandi et al., Proc. Natl Acad Sci. USA 1989, 86: 3833. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones et al., Nature 1986, 321: 522; Carter et al., Proc. Natl. Acad. Sci. USA 1992, 89: 4285; Sandhu, Crit. Rev. Biotech. 1992, 12: 437; Singer et al., J. Immun. 1993, 150:
10 2844 and U.S. Patent No. 5,693,762.

An alternative therapy regimens may be the use of cDNA or cRNA sequences of TTP or portions thereof. Protective end groups and naturally occurring
15 modifications to the RNA or DNA moieties provide further stability allowing the molecules to be effective over several days. Such modified DNA or RNA moieties are commercially available from ATUGEN, Berlin, Germany.

Such modified or unmodified cDNA or cRNA may be used for the hybridization with TTP mRNA and therefore for the suppression of TTP production.
20

Delivery of the nucleic acid to cells can be via a variety of mechanisms. The nucleic acid can be present in combination with any agent which aids in the introduction of the DNA into cells. Various sterile solutions may be used for administration of the composition, including water, PBS, etc. The concentration of
25 the DNA will be sufficient to provide a therapeutic dose.

Actual delivery of the cDNA, cRNA, antibodies or fragments thereof, formulated as described above, can be carried out by a variety of techniques including direct injection, administration to the lung and other epithelial surfaces, intravenous
30 injection and other physical methods.

An example for a suitable transfer method according to the present invention is the physical transfer of cDNA or cRNA in liposomes or lipid mixtures using

26474-862

- 18 -

commercially available liposome preparations or lipid mixtures such as Lipofectine^{*}, Lipofectamine^{*} (GIBCO-BRL, Inc., Gaithersburg, MD), Superfecto^{*} (Qiagen, Inc. Hilden, Germany) and Transfectarno^{*} (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. directly into target cells. Once in the cell, the cDNA or cRNA complementary to the TTP mRNA binds to TTP mRNA and inhibits translation of TTP which results in a increase of TNF α production. Such lipid mixtures are also commercially available from ATUGEN, Berlin, Germany. Liposome-mediated DNA transfer has been described by various investigators (Liu et al, Gene Therapy 1994, 1:7; Miller and Vile, FASEB J. 1995, 9:190).

The exact method of introducing the nucleic acid into mammalian cells is, of course, not limited to the method described above. Other techniques are widely available for this procedure including the use such as receptor-mediated and other endocytosis mechanism. This invention can be used in conjunction with any of these or other commonly used transfer methods.

The nucleic acids and nucleic acid delivery vehicles of this invention, can be in a pharmaceutically acceptable carrier for in vivo administration to a subject. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vehicle, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

The nucleic acid or vehicle may be administered orally, parenterally (e.g. , intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like. The exact amount of the nucleic acid or vector required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity or

*Trade-mark

26474-862

- 19 -

mechanism of any disorder being treated, the particular nucleic acid or vehicle used, its mode of administration and the like.

The compounds selected by an assay as described above, anti-TTP antibodies
5 and fragments thereof can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, subcutaneous injection, transdermally, extracorporeally, topically, mucosally or the like.

10 Depending on the intended mode of administration, the compounds of the present invention can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, gels, or the like, preferably in unit dosage form suitable for single administration of a precise
15 dosage. The compositions will include, as noted above, an effective amount of the selected composition, possibly in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. Parenteral administration of the compounds of the present invention, if used, is generally
20 characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. As used herein, "parenteral administration" includes intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous and intratracheal routes. A more recently revised
25 approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795. These compounds can be present in a pharmaceutically acceptable carrier, which can also include a suitable adjuvant. By "pharmaceutically acceptable" is meant a
30 material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected compound without causing substantial deleterious biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.

Unit doses according to the invention may contain daily required amounts of the compound according to the invention, or sub-multiples thereof to make up the desired dose. The optimum therapeutically acceptable dosage and dose rate for
5 a given patient (mammals, including humans) depends on a variety of factors, such as the activity of the specific active compound employed, the age, body weight, general health, sex, diet, time and route of administration, rate of clearance, the object of the treatment, i. e., therapy or prophylaxis and the nature of the disease to be treated which are known to the skilled person.

10

Therefore, in compositions and combinations in a treated patient (in vivo) a pharmaceutical effective daily dose of the active compound of this invention is between about 0.01 and 100 mg/kg body weight, preferably between 0.1 and 10 mg/kg body weight. According to the application form one single dose may
15 contain between 0.01 and 10 mg of the active compound.

Example

In anesthetized, open-chest dogs, the second window of protection of ischemic
20 preconditioning was investigated. The dogs were instrumented for measurement of left ventricular pressure and aortic pressure. The dogs were subjected to 5 min of coronary occlusion of the left anterior descending coronary artery perfusing the anterior wall followed either by 4hrs, 8hrs or 16 hrs of reperfusion. A second set of dogs (control group) were not subjected to coronary occlusion. Following the
25 experimental protocol, transmural blocks of myocardial tissue from the center of the anterior wall and the posterior control wall were taken and immediately frozen. To identify mRNAs that are upregulated in dog hearts that underwent occlusion followed by reperfusion for different time periods, RNAs from these hearts were subjected to RDA (representational difference analysis). The method
30 is designed to identify mRNAs that are present in higher amounts in the first, often the treated, tissue (designated as 'tester') than in the second tissue (designated as driver). RNA from shock-frozen left ventricular myocardium was extracted by using a standard guanidinium thiocyanate extraction, followed by centrifugation in a cesium chloride gradient (Pharmacia, LKB, Freiburg,

26474-862

- 21 -

Germany). Poly(A)-RNA was isolated by using oligo-d(T) coupled to magnetic beads (DYNABEADS*, Dynal, Norway) according to the manufacturer's instructions. To overcome individual alterations in gene expression mRNA from three non-failing control hearts (Driver) and three failing hearts (Tester) were compared as well as a pooled sample. After reverse transcription (cDNA synthesis system, Gibco) double-stranded cDNAs were digested with DpnII, ligated to linkers, amplified, and subtracted as described for RDA (Hubank, M. and Schatz, D.G. (1994): Nucleic Acids Res.,22, 5640-5648) with minor modifications (Frohme et al.(2000): Ann N Y Acad Sci., 910, 85-104). Three rounds of subtractive hybridization were performed resulting in difference product 2 and 3 which were cloned into pBluescript II-SK+ in DH5alpha* E.coli. Inserts of the clone libraries were amplified by standard PCR for gel analysis. Sequencing followed standard procedures for the automated sequencer (Applied Biosystems, USA). BLASTX and BLASTN analyses were used to screen for DNA and protein homologies of the sequences identified.

*Trade-mark

26474-862

- 22 -

CLAIMS:

1. A method for screening a compound for its ability to enhance TNF α production by inhibiting and/or reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

5 a) contacting the compound with a cell-free sample comprising an expression construct able to express a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE fragments known to destabilize the TNF α mRNA fused to a reporter gene in the presence of TTP under conditions such that the reporter protein can be expressed; and

10 b) determining the level of expression of the reporter protein and comparing that level to a level of expression obtained in the absence of the compound; and

c) selecting compounds which enhance the expression of the reporter protein in comparison to that level of expression obtained in the absence of the
15 compound.

2. A method for screening a compound for its ability to enhance TNF α production by inhibiting and/or reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

a) contacting said compound with a cell-free sample comprising TNF α
20 mRNA, in the presence of TTP under conditions such that TNF α can be expressed;

b) determining the level of expression of TNF α and comparing the level of produced TNF α to a level of TNF α obtained in the absence of said compound; and

c) selecting compounds which enhance the expression of TNF α in comparison to that level of expression obtained in the absence of the compound.

26474-862

- 23 -

3. A method for screening a compound for its ability to enhance TNF α production by inhibiting and/or reversing the binding of tristetraproline (TTP) to TNF α mRNA comprising:

- 5 a) contacting the compound with a cell line expressing TTP and TNF α or, instead of TNF α , a part of the 3' untranslated region of the TNF α mRNA which encompasses the ARE fragments known to destabilize the TNF α mRNA fused to a reporter gene;
- b) determining the level of expression of TNF α or of the reporter protein and comparing that level to a level of expression obtained in the absence of the
10 compound; and
- c) selecting compounds which enhance the expression of TNF α or the expression of the reporter protein in comparison to that level of expression obtained in the absence of the compound.

4. Use of the cDNA or cRNA complementary to the mRNA of
15 tristetraproline (TTP), or of anti-TTP antibodies, to induce or enhance TNF α production in an individual by one or both of inhibiting and reversing the binding of TTP to TNF α mRNA, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA.

20 5. Use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, for the manufacture of a medicament to induce or enhance TNF α production in an individual by one or both of inhibiting and reversing the binding of TTP to TNF α mRNA, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP
25 antibodies inhibit binding of TTP to TNF α mRNA.

6. Use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, for the treatment of one or both of

26474-862

- 24 -

cardiac diseases and cardiac injuries, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA, and wherein one or both of the cardiac disease and cardiac injury is a hemodynamic overloading, myocardial reperfusion injury,

5 hypertrophic cardiomyopathy, end-stage congestive heart failure, ischemic condition, myocardial infarction or unstable angina.

7. Use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, for the manufacture of a medicament for the treatment of one or both of cardiac diseases and cardiac injuries, wherein the
10 cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA, and wherein one or both of the cardiac disease and cardiac injury is a hemodynamic overloading, myocardial reperfusion injury, hypertrophic cardiomyopathy, end-stage congestive heart failure, ischemic condition, myocardial infarction or unstable angina.

15 8. Use of the cDNA or cRNA complementary to the mRNA of tristetraproline (TTP), or of anti-TTP antibodies, for the prevention of reperfusion damage, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA.

9. Use of the cDNA or cRNA complementary to the mRNA of
20 tristetraproline (TTP), or of anti-TTP antibodies, for the manufacture of a medicament for the prevention of reperfusion damage, wherein the cDNA or the cRNA binds to TTP mRNA and inhibits translation of TTP and wherein the anti-TTP antibodies inhibit binding of TTP to TNF α mRNA.

Fig. 1

